Atlas Trials

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

Clinical trial NCT03330691 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03330691
Sponsor
Seattle Children's Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
LeukemiaLymphoma
Start date
2017-11-03
Primary completion
2023-09-13
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.